user
menu
letter
Sign InRegister
langEnglisharrow
1/10
+7 View all
COADS MSDS

GMP Human IL-15 Protein

DMF
Premium grade (Pre-GMP) version IL5-H4117 is now available for seamless transition.
1/10
+7 View all
COADS MSDS
Cat. No. / Size
Price
Availability
Qty
GMP lyophilized
GMP-L15H13-50ug
$855.00
In Stock - Delivery in 1-2 business days
GMP-L15H13-1mg (50ug X 20)
$7,325.00
In Stock - Delivery in 1-2 business days
GMP-L15H13-10mg (50ug X 200)
$51,275.00
Inquire about delivery time
CytoPak
GMP-L15H13GB01-10ug
$370.00
In Stock - Delivery in 1-2 business days
CytoPak
GMP-L15H13GB02-50ug
Inquire
In Stock - Delivery in 1-2 business days
GMP-L15H13
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Important Statement
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
GMP Platform Advantages
  • Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
  • End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
  • Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
  • Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
  • Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
  • Professional Support: Extensive manufacturing and application expertise to accelerate development.
Source

GMP Human IL-15 Protein (GMP-L15H13) is expressed from E. coli cells. It contains AA Asn 49 - Ser 162 (Accession # P40933-1).

Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version

This protein carries no "tag".

The protein has a calculated MW of 12.9 kDa. The protein migrates as 13 kDa±3 kDa under reducing (R) condition (SDS-PAGE).

N-terminal Sequence Analysis

Met-Asn-Trp-Val-Asn-Val-Ile-Ser-Asp-Leu-Lys-Lys-Ile-Glu-Asp
(Routinely tested)

Endotoxin

Less than 10 EU/mg, tested by the LAL method in compliance with USP <85> and Ph. Eur. 2.6.14.

Host Cell Protein

<0.5 ng/µg of protein tested by ELISA.

Host Cell DNA

<0.02 ng/μg of protein tested by DNA Fluorescent Staining method.

Sterility

Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

Mycoplasma

Negative

In vitro virus assay

Negative.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in 25 mM His, pH6.2 with protectants.

Contact us for customized product form or formulation.

Vial Specification

2R (13 mm neck finish)

Shipping and Storage

This product is supplied and shipped on blue ice.

Upon receipt, store it immediately at -20°C or lower for long term storage.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 5 years in lyophilized state;
  • -70°C for 12 months under sterile conditions after reconstitution.
ACRO Quality Management System

Background

Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.